查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930120

全球帶狀皰疹疫苗市場：市場規模、佔有率、成長率、行業分析、依類型、應用和地區劃分的考察、未來預測（2026-2034）

Shingles Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

帶狀皰疹疫苗市場成長因素

受疾病流行率上升、人口老化以及成人預防性免疫意識增強的推動，全球帶狀皰疹疫苗市場在2025年基準年呈現顯著成長。報告顯示，2025年市場規模為56.7億美元。在先進疫苗不斷推出和疫苗接種覆蓋範圍擴大的推動下，預計2026年市場規模將成長至59.5億美元，到2034年將進一步成長至129.2億美元。北美地區憑藉著較高的市場意識、完善的醫療保健基礎設施以及重組帶狀皰疹疫苗的廣泛應用，在2025年佔據全球市場36.98%的市場佔有率。

帶狀皰疹疫苗用於預防帶狀皰疹，這是一種由水痘-帶狀皰疹病毒再活化引起的疼痛且常導致殘疾的疾病。該病毒在人類感染水痘後可能處於潛伏狀態，並在日後再次活化，尤其是在老年人和免疫功能低下的人群中。接種疫苗（需接種兩劑）仍然是預防帶狀皰疹及其併發症的唯一有效方法。

市場動態

市場驅動因素

2025年至2026年，全球帶狀皰疹發生率的上升是推動市場成長的主要因素。老化和免疫老化會顯著增加對帶狀皰疹的敏感性，導致對疫苗的需求增加。根據2023年9月發布的資料，年輕健康成年人中帶狀皰疹的發生率在每年每千人1.2至3.4例之間，老年人群的發生率更高。同時，公眾意識的提高和衛生部門的建議進一步促進了疫苗接種。

市場限制因子

帶狀皰疹疫苗的副作用仍然是一個限制因素。不良反應，例如注射部位疼痛、疲勞、發燒和罕見的神經系統症狀，會影響患者的信心。2023年，加拿大因安全問題暫停了Zostavax的銷售，這凸顯了耐受性問題如何影響市場動態，並引發對更安全替代方案的需求轉變。

市場機會

解決成本障礙是關鍵的成長機會。高昂的疫苗價格和有限的保險覆蓋範圍阻礙了疫苗在一些地區的廣泛應用。截至2025年2月，印度兩劑SHINGRIX疫苗的價格在300至400美元之間，限制了疫苗的普及。降價、政府補貼和擴大償付範圍預計在2034年之前促進市場成長，並顯著提高疫苗接種率。

市場挑戰

某些地區疫苗認知度低和接種管道有限，對市場擴張構成挑戰。根據2023年10月發布的一項研究，57.2%的目標族群了解帶狀皰疹疫苗，但接種率僅7.7%。認知度和接種管道的差異對實現最佳疫苗覆蓋率構成挑戰。

帶狀皰疹疫苗市場趨勢

影響全球市場的關鍵趨勢是重組次單位疫苗的日益普及。像SHINGRIX這樣的非活性疫苗因其卓越的療效和安全性，尤其是在老年人和免疫功能低下人群中，正成為更受歡迎的選擇。2024年7月發表的臨床資料證實，重組疫苗不僅能預防帶狀皰疹，還能顯著降低帶狀皰疹後神經痛的風險，進一步鞏固了其市場地位。

市場區隔分析

依類型

重組/結合/次單位疫苗在2024年佔據市場主導地位，並在2034年之前保持最快的成長速度。這些疫苗在提供高保護率的同時，也避免了減毒活疫苗的相關風險。 "其他" 疫苗類別，包括基於mRNA的疫苗，也正受到越來越多的關注，目前已有多個候選疫苗進入臨床試驗階段。

依產品

2024年，SHINGRIX疫苗憑藉其強大的臨床療效，佔據了最大的市場佔有率。2024年7月發布的資料顯示，SHINGRIX疫苗在預防50-69歲成年人帶狀皰疹方面的有效率高達97%，鞏固了其領先地位。該細分市場的剩餘部分由在研產品構成，包括基於mRNA的疫苗。

依通路劃分

在國家疫苗接種計劃和優惠的償付政策的推動下，政府機構在2024年佔據了市場主導地位。由於公私合作的增加以及城市醫療保健服務可近性的提高，醫院和零售藥局預計將繼續佔據相當大的市場佔有率。

區域展望

北美

在疾病高發生率且強有力的疫苗接種計畫的推動下，北美市場在2025年達到21億美元，預計在2026年達到21.6億美元。美國每年約有100萬例帶狀皰疹病例，在該地區位居榜首，支撐著持續的疫苗需求。

歐洲

歐洲擁有第二大市場佔有率，這得益於有利的償付機制和區域性的宣傳活動。歐盟各國的合作活動提高成人疫苗接種率。

亞太地區

亞太地區是成長最快的地區，這主要得益於人口老化、可支配收入增加以及政府主導的疫苗接種活動的擴大。主要生產商所進行的宣傳活動也推動市場成長。

拉丁美洲、中東和非洲

由於醫療保健服務的改善、公眾意識的提高以及先進帶狀皰疹疫苗的逐步推廣，預計這些地區的市場將保持穩定成長。

帶狀皰疹疫苗市場報告對2025年、2026年和2034年的市場價值進行了嚴格的預測，並提供了全面的分析。報告涵蓋了市場動態、依類型、產品和通路劃分的市場細分、區域表現、競爭格局和關鍵發展，對預測期內的市場演變提供了詳細的分析。

展望未來，預計到2034年，帶狀皰疹疫苗市場規模將達到129.2億美元。這一成長主要得益於人口老化帶來的持續需求、非活性疫苗平台的技術進步以及包括基於mRNA的帶狀皰疹疫苗在內的在研產品線。儘管在某些地區，成本障礙、副作用和區域認知度不均仍然是挑戰，但政府支持的增加、償付政策的完善以及公私合作的推進有望提高疫苗的可及性和普及率。總體而言，帶狀皰疹疫苗市場預計將在預測期內保持長期穩定的價值成長，繼續在成人免疫和醫療保健領域發揮重要作用。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 帶狀皰疹（皰疹病毒感染）的流行病學
  • 主要國家的償付情況
  • 主要公司的產品線分析
  • 主要公司的新產品發布
  • 關鍵產業趨勢：併購、業務合作等

章節5 全球帶狀皰疹疫苗市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依類型
    • 重組/結合/次單位疫苗
    • 其他
  • 市場分析、洞察與預測：依產品
    • SHINGRIX
    • 其他
  • 市場分析、洞察與預測：依銷售管道
    • 醫院和零售藥局
    • 政府供應商
    • 其他
  • 市場分析、洞察與預測：依地區
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美帶狀皰疹疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第7章 歐洲帶狀皰疹疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第8章 亞太地區帶狀皰疹疫苗市場分析：洞察與預測（2021-2034）

  • 依國家/地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 亞太其他地區

第9章 拉丁美洲帶狀皰疹疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第10章 中東與非洲帶狀皰疹疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • GCC國家
    • 南非
    • 中東其他地區非洲

第11章 競爭分析

  • 全球市場佔有率分析（2025）
  • 公司簡介
    • GSK plc
    • Moderna Inc.
    • Jiangsu Recbio Technology Co., Ltd.
    • Pfizer Inc.
    • Dynavax Technologies
    • Curevo Inc.
Product Code: FBI102072

Growth Factors of Shingles Vaccines Market

The global Shingles Vaccines Market demonstrated strong expansion in the base year 2025, driven by rising disease prevalence, increasing geriatric population, and growing awareness regarding preventive adult immunization. According to the report, the market size was valued at USD 5.67 billion in 2025. With continued uptake of advanced vaccines and broader immunization coverage, the market is projected to grow to USD 5.95 billion in 2026 and further expand to USD 12.92 billion by 2034. North America dominated the global landscape with a 36.98% market share in 2025, supported by high awareness levels, strong healthcare infrastructure, and widespread adoption of recombinant shingles vaccines.

Shingles vaccines are used to prevent herpes zoster, a painful and often debilitating condition caused by reactivation of the varicella-zoster virus. The virus remains dormant after an individual recovers from chickenpox and can reactivate later in life, particularly among older adults and immunocompromised populations. Vaccination, administered in a two-dose schedule, remains the only effective preventive measure against shingles and its complications.

Market Dynamics

Market Drivers

The rising incidence of shingles globally is a primary factor driving market growth across 2025 and 2026. Aging populations and immunosenescence significantly increase susceptibility to shingles, resulting in higher vaccine demand. Data published in September 2023 indicated a shingles prevalence rate of 1.2-3.4 cases per 1,000 persons per year among younger healthy adults, with substantially higher rates in older populations. In parallel, increasing awareness campaigns and recommendations from health authorities further boost vaccine adoption.

Market Restraints

Side effects associated with shingles vaccines remain a limiting factor. Adverse reactions such as injection-site pain, fatigue, fever, and rare neurological conditions can affect patient confidence. In 2023, Canada discontinued Zostavax due to safety concerns, highlighting how tolerability issues can influence market dynamics and shift demand toward safer alternatives.

Market Opportunities

Addressing cost barriers represents a major growth opportunity. High vaccine prices and limited insurance coverage restrict uptake in several regions. In February 2025, the cost of two doses of SHINGRIX in India ranged between USD 300-400, limiting accessibility. Price reductions, government subsidies, and reimbursement expansion could significantly improve adoption rates and support market growth toward 2034.

Market Challenges

Limited awareness and restricted access in certain regions challenge market expansion. Studies published in October 2023 showed that while 57.2% of participants were aware of the shingles vaccine in selected populations, only 7.7% had received it. Such gaps in awareness and access continue to hinder optimal vaccine coverage.

Shingles Vaccines Market Trends

A key trend shaping the global market is the increasing adoption of recombinant subunit vaccines. Non-live vaccines such as SHINGRIX are preferred due to their superior efficacy and safety profile, particularly for older and immunocompromised individuals. In July 2024, clinical data confirmed that recombinant vaccines not only prevent shingles but also significantly reduce the risk of postherpetic neuralgia, reinforcing their growing dominance.

Segmentation Analysis

By Type

The recombinant/conjugate/subunit segment dominated the market in 2024 and is expected to register the fastest growth through 2034. These vaccines offer high protection without the risks associated with live attenuated formulations. The "others" segment, including mRNA-based vaccines, is gaining attention, with multiple candidates entering clinical trials.

By Product

The SHINGRIX segment held the largest market share in 2024, supported by strong clinical efficacy. Data published in July 2024 showed SHINGRIX to be 97% effective in preventing shingles among adults aged 50-69 years, reinforcing its leadership position. Pipeline products, including mRNA-based vaccines, form the remainder of the segment.

By Distribution Channel

Government suppliers dominated the market in 2024, driven by national immunization initiatives and favorable reimbursement policies. Hospital and retail pharmacies are expected to maintain significant shares due to increasing public-private partnerships and improved access in urban healthcare settings.

Regional Outlook

North America

North America generated USD 2.10 billion in 2025 and USD 2.16 billion in 2026, driven by high disease prevalence and strong vaccination programs. The U.S. leads the region, with approximately 1 million shingles cases annually, supporting sustained vaccine demand.

Europe

Europe holds the second-largest share, supported by favorable reimbursement frameworks and region-wide awareness initiatives. Collaborative campaigns have strengthened adult vaccination coverage across EU countries.

Asia Pacific

Asia Pacific is the fastest-growing region, supported by rising elderly populations, increasing disposable income, and expanding government-backed immunization efforts. Awareness campaigns by leading manufacturers further support growth.

Latin America and Middle East & Africa

These regions are expected to witness steady growth, driven by improving healthcare access, rising awareness, and gradual introduction of advanced shingles vaccines.

Competitive Landscape

The market is led by GSK plc. and Pfizer Inc., which together account for a significant share. GSK's SHINGRIX remains the most widely adopted product globally, supported by regulatory approvals and awareness initiatives. Pfizer, in collaboration with BioNTech, is advancing mRNA-based shingles vaccines. Other notable players include Moderna Inc., Dynavax Technologies, Jiangsu Recbio Technology Co., Ltd., and Curevo Inc., all actively investing in next-generation vaccine development.

Report Coverage

The shingles vaccines market report provides a comprehensive analysis aligned strictly with 2025, 2026, and 2034 market values. It covers market dynamics, segmentation by type, product, and distribution channel, regional performance, competitive landscape, and key industry developments, offering a detailed view of market evolution across the forecast period.

Conclusion

The global Shingles Vaccines Market exhibits a strong and well-supported growth outlook across the report years, driven by rising shingles incidence, demographic aging, and increasing emphasis on adult preventive immunization. Valued at USD 5.67 billion in 2025, the market reflects growing acceptance of vaccination as the most effective preventive strategy against herpes zoster and its long-term complications. The steady rise to USD 5.95 billion in 2026 highlights continued short-term expansion supported by awareness initiatives, strong government participation, and high adoption of recombinant subunit vaccines, particularly in North America, which accounted for 36.98% of the global market in 2025.

Looking ahead, the projected expansion to USD 12.92 billion by 2034 is underpinned by sustained demand from aging populations, technological advancements in non-live vaccine platforms, and pipeline developments such as mRNA-based shingles vaccines. While challenges related to cost barriers, side effects, and uneven awareness persist across certain regions, increasing government support, reimbursement policies, and public-private collaborations are expected to enhance accessibility and uptake. Overall, the shingles vaccines market is positioned for consistent long-term value growth, maintaining its critical role in adult immunization and preventive healthcare throughout the forecast period.

Segmentation

By Type

  • Recombinant/Conjugate/Subunit
  • Others

By Product

  • SHINGRIX
  • Others

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Product, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Product, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Product, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • o
    • Rest of Asia Pacific
  • Latin America (By Type, Product, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Product, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Epidemiology of Shingles (Herpes Zoster)
  • 4.2. Reimbursement Scenario, By Key Countries/Regions
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. New Product Launches, By Key Players
  • 4.5. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Recombinant/Conjugate/Subunit
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - Product
    • 5.2.1. SHINGRIX
    • 5.2.2. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital & Retail Pharmacies
    • 5.3.2. Government Suppliers
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Recombinant/Conjugate/Subunit
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - Product
    • 6.2.1. SHINGRIX
    • 6.2.2. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital & Retail Pharmacies
    • 6.3.2. Government Suppliers
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Recombinant/Conjugate/Subunit
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - Product
    • 7.2.1. SHINGRIX
    • 7.2.2. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital & Retail Pharmacies
    • 7.3.2. Government Suppliers
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Recombinant/Conjugate/Subunit
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - Product
    • 8.2.1. SHINGRIX
    • 8.2.2. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital & Retail Pharmacies
    • 8.3.2. Government Suppliers
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Recombinant/Conjugate/Subunit
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - Product
    • 9.2.1. SHINGRIX
    • 9.2.2. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital & Retail Pharmacies
    • 9.3.2. Government Suppliers
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Recombinant/Conjugate/Subunit
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - Product
    • 10.2.1. SHINGRIX
    • 10.2.2. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital & Retail Pharmacies
    • 10.3.2. Government Suppliers
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Moderna Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Jiangsu Recbio Technology Co., Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Pfizer Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Dynavax Technologies
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Curevo Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 3: Global Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Shingles Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 6: North America Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 7: North America Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Shingles Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 10: Europe Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 11: Europe Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Shingles Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 13: Asia Pacific Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Asia Pacific Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 15: Asia Pacific Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Shingles Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 17: Latin America Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 18: Latin America Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 19: Latin America Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Shingles Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 21: Middle East & Africa Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Middle East & Africa Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 23: Middle East & Africa Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Shingles Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034

List of Figures

  • Figure 1: Global Shingles Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Shingles Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Shingles Vaccines Market Value Share (%), by Product, 2025 & 2034
  • Figure 4: Global Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Shingles Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Shingles Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 7: North America Shingles Vaccines Market Value Share (%), by Type, 2025
  • Figure 8: North America Shingles Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 9: North America Shingles Vaccines Market Value Share (%), by Product, 2025
  • Figure 10: North America Shingles Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Shingles Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Shingles Vaccines Market Value Share (%), By Country, 2025
  • Figure 14: Europe Shingles Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 15: Europe Shingles Vaccines Market Value Share (%), by Type, 2025
  • Figure 16: Europe Shingles Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 17: Europe Shingles Vaccines Market Value Share (%), by Product, 2025
  • Figure 18: Europe Shingles Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Shingles Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 21: Europe Shingles Vaccines Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 22: Asia Pacific Shingles Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Asia Pacific Shingles Vaccines Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific Shingles Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 25: Asia Pacific Shingles Vaccines Market Value Share (%), by Product, 2025
  • Figure 26: Asia Pacific Shingles Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Shingles Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 29: Asia Pacific Shingles Vaccines Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 30: Latin America Shingles Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 31: Latin America Shingles Vaccines Market Value Share (%), by Type, 2025
  • Figure 32: Latin America Shingles Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 33: Latin America Shingles Vaccines Market Value Share (%), by Product, 2025
  • Figure 34: Latin America Shingles Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Shingles Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 37: Latin America Shingles Vaccines Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 38: Middle East & Africa Shingles Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 39: Middle East & Africa Shingles Vaccines Market Value Share (%), by Type, 2025
  • Figure 40: Middle East & Africa Shingles Vaccines Market Value (USD billion), by Product, 2025 & 2034
  • Figure 41: Middle East & Africa Shingles Vaccines Market Value Share (%), by Product, 2025
  • Figure 42: Middle East & Africa Shingles Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Shingles Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 45: Middle East & Africa Shingles Vaccines Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 46: Global Shingles Vaccines Market Share (%), By Company, 2025